Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 537 Issue 7618, 1 September 2016

Amyloid plaque reduction with aducanumab, seen in example amyloid PET images at baseline and week 54. Aducanumab is a recombinant human monoclonal antibody that selectively targets the amyloid- (A) peptide aggregates thought to play a part in the neurodegenerative process in Alzheimer’s disease. Several Alzheimer’s disease drugs have faltered during development in recent years, so there is intense interest in any new results. A new study reports interim results from a clinical trial of monthly infusions of aducanumab in subjects with prodromal or mild Alzheimer’s disease. Treatment with aducanumab reduced brain A plaques, an action accompanied by a dose-dependent slowing of clinical decline. The trial data support further development of aducanumab as an A-removing therapy.

Editorial

Top of page ⤴

World View

Top of page ⤴

Research Highlights

Top of page ⤴

Seven Days

Top of page ⤴

News

Top of page ⤴

News Feature

Top of page ⤴

Comment

Top of page ⤴

Books & Arts

Top of page ⤴

Correspondence

Top of page ⤴

News & Views

  • An antibody therapy markedly reduces aggregates of amyloid-β, the hallmark protein of Alzheimer's disease, and might slow cognitive decline in patients. Confirmation of a cognitive benefit would be a game-changer. See Article p.50

    • Eric M. Reiman
    News & Views
  • The Rosetta spacecraft made history by successfully orbiting a comet. Data from the craft now reveal the structure of the comet's dust particles, shedding light on the processes that form planetary systems. See Letter p.73

    • Ludmilla Kolokolova
    News & Views
  • Production of the cell's translational apparatus, the ribosome, requires the orchestrated function of hundreds of proteins. A structure of its earliest precursor yields unprecedented insight into ribosome formation.

    • Marlene Oeffinger
    News & Views
  • The Southern Ocean has become less salty during the past few decades. An analysis of sea-ice transport in the ocean suggests that this phenomenon can be explained by coupled changes in sea-ice drift and thickness. See Letter p.89

    • Ted Maksym
    News & Views
  • If a tumour outgrows its blood supply, oxygen levels in its cells decrease. It emerges that this change can alter gene expression by limiting the activity of TET enzymes, which remove methyl groups from DNA. See Article p.63

    • Dan Ye
    • Yue Xiong
    News & Views
  • When and by which paths did early humans migrate into America? An analysis of ancient plant and animal remains revises the timeframe during which a route may have opened between ice sheets in northwest America. See Article p.45

    • Suzanne McGowan

    Collection:

    News & Views
Top of page ⤴

Article

Top of page ⤴

Letter

Top of page ⤴

Corrigendum

Top of page ⤴

Toolbox

  • Software tools that digitize and annotate underwater images are transforming marine ecology.

    • Jeff Tollefson

    Collection:

    Toolbox
Top of page ⤴

Feature

Top of page ⤴

Futures

  • A sense of loss.

    • Bo Balder
    Futures
Top of page ⤴

Brief Communications Arising

Top of page ⤴

Outlook

Top of page ⤴
Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links